Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-Fluoro-3-pyridinecarboxylic acid is a small molecule compound with the molecular formula C6H4FNO2. It is also known as 5-fluoronicotinic acid and features a pyridine ring substituted with a fluorine atom at the 5-position and a carboxylic acid group at the 3-position. The compound has been investigated in clinical trials up to phase III for unspecified indications. Its mechanism of action and primary therapeutic use are not clearly established in public sources; it may serve as an intermediate or research chemical rather than an approved pharmaceutical agent. The substance is classified as hazardous due to its potential to cause skin irritation, serious eye irritation, and respiratory tract irritation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluoro-3-pyridinecarboxylic acid.